Curtain Closes on Takeda’s Cell Therapy Efforts
Takeda has decided to discontinue all its cell therapy research efforts as part of a strategic portfolio prioritization process125.
The company will seek an external partner to leverage its existing cell therapy platform technologies and advance its research and clinic-ready programs in this field123.
Takeda currently has no active clinical trials involving cell therapy technology13.
The discontinuation will result in an impairment loss of approximately 58.0 billion yen (around US$390 million) in the second quarter of fiscal 2025, primarily related to intangible assets associated with the gamma delta T-cell therapy platform12.
Most of this impact is expected to be absorbed by prior impairment losses included in Takeda's consolidated FY2025 forecast12.
Takeda will now focus near-term investments on other modalities such as small molecules, biologics, and antibody-drug conjugates, aiming to deliver transformative therapies more efficiently14.
Sources:
1. https://www.takeda.com/newsroom/statements/2025/takeda-provides-update-on-cell-therapy-research/
2. https://www.nasdaq.com/articles/takeda-discontinue-cell-therapy-efforts-recognize-impairment-loss-q2
3. https://www.fiercebiotech.com/biotech/takeda-taps-out-cell-therapy-arena-part-strategic-shift
4. https://news.futunn.com/en/post/62848863/takeda-pharmaceutical-discontinues-cell-therapy-research-program